$37M to Speed Age-Related Disease Cures to Patients

Scientists studying how we age just got a massive boost to bring their breakthroughs out of the lab and into patients' lives.

Brown University and Brown University Health are launching the Starr Healthspan Innovation Alliance with $37 million from the Starr Foundation. The partnership aims to speed up the journey from discovery to treatment for major age-related diseases.

Here's what makes this different. Instead of researchers working separately from doctors, the alliance connects Brown's aging biology labs directly with the hospital system's clinical trial network. That means promising treatments can reach patients years faster than the traditional path.

The funding will expand Brown's Center on the Biology of Aging and recruit leading researchers in geroscience. That's the study of what happens to our genes, cells, and molecules as we age. Understanding these mechanisms helps scientists target the root causes of diseases like cancer, dementia, and other conditions that become more common as we get older.

The money will also grow the number of clinical trials happening across Brown University Health hospitals. More trials mean more Rhode Island patients get access to cutting-edge treatments while helping researchers learn what works.

Brown University President Christina Paxson says the investment supports a bold vision for medicine focused on helping people live fuller, healthier lives as they age. The goal isn't just adding years to life but making those years vibrant and disease-free.

The alliance builds on partnerships already working between Brown's Warren Alpert Medical School and teaching hospitals. In 2022, Brown created a system to align university research with clinical partners. They expanded that collaboration in 2024 to strengthen patient care, medical education, and research throughout Rhode Island.

The Ripple Effect

This investment does more than fund labs and trials. It creates an ecosystem where breakthroughs flow naturally from bench to bedside. When researchers and clinicians work side by side, they spot opportunities faster and solve problems together. Patients benefit from treatments informed by the latest science, while scientists get real-world feedback that sharpens their research.

The focus on healthspan rather than just lifespan represents a shift in how medicine approaches aging. Instead of treating diseases one at a time as they appear, researchers are targeting the biological processes that make us vulnerable to multiple conditions as we age.

Rhode Island stands to become a hub for this emerging field, attracting top talent and giving local patients early access to tomorrow's treatments.

Thirty-seven million dollars buys more than equipment and salaries—it buys hope that the next breakthrough won't take decades to reach the people who need it most.